Prof. Dr. Markus Diefenbacher
LMU Professor of Immuno-Oncology of the Lung and Pleura, Head of Helmholtz Research Group “Experimental Oncology”

Topic: The Ubiquitin System as a targetable entity in Lung Cancer
Prof. Dr. Markus Diefenbacher is a group leader at the Helmholtz Munich Institute of Lung Health and Immunity and the Institute of Experimental Pneumology at LMU. He was awarded the IZKF Research Award in 2017 and is a PI at the DKTK (German Consortium for Translational Cancer Research-Munich).

Markus Diefenbacher’s work focuses on the deregulation of protein turnover as a central driver in tumourigenesis. By utilising in vitro and in vivo models, his lab aims to understand the role of key components of the ubiquitylation machinery in order to find ways to counteract deregulation of protein stability as a therapeutic approach.

Dr. Rüdiger Jankowsky
CEO AATec Medical

Topic: New therapeutics for inflammatory respiratory diseases
Inflammatory airway diseases represent a major global health challenge. Hundreds of millions of patients suffer from COPD, asthma, bronchiectasis, pulmonary fibrosis, and other conditions of the lungs. While treatment options remain limited, recent years have seen significant advances in new approaches. Dr. Rüdiger Jankowsky, CEO of AATec, will provide an overview of emerging treatment modalities and explain how AATec develops new biotherapeutics for the rapidly growing area of inflammatory lung diseases.

Anne Burger
CFO CatalYm

Dominik Schumacher
CEO Tubulis